WHO Assembly RejectsBudget Requirements

21 May 1995

The annual assembly of the World Health Organization, meeting in Geneva, Switzerland, this month, has approved a budget of $922 million for the 1996/97 period. However, this is significantly below the WHO's stated requirement in the face of inflation and the weak US dollar. The WHO had requested a 16.2% increase on its previous budget, but the figure approved represents a rise of just 2.5%.

WHO Director General Hiroshi Nakajima came under continued criticism at the assembly, particularly following the resignation of Sir John Bourn, head of the UK's National Audit Office, as external auditor of the WHO. Sir John complained there had been a lack of cooperation from the WHO leadership. His resignation was also accompanied by allegations of fraud in the WHO Africa office and a challenge to Dr Nakajima's leadership of the WHO.

WHO procedures and travel arrangements were criticized by Sir John, who also claimed that his staff had encountered increasingly contentious attitudes from the Secretariat. In turn, this led to a "complete withdrawal of dialog and cooperation" in the finalization of Sir John's report, which he said makes it impossible for him to continue with his contract.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight